CN113521208A - 一种用于治疗高同型半胱氨酸血症的组合物 - Google Patents
一种用于治疗高同型半胱氨酸血症的组合物 Download PDFInfo
- Publication number
- CN113521208A CN113521208A CN202110795802.6A CN202110795802A CN113521208A CN 113521208 A CN113521208 A CN 113521208A CN 202110795802 A CN202110795802 A CN 202110795802A CN 113521208 A CN113521208 A CN 113521208A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- composition
- hyperhomocysteinemia
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000033892 Hyperhomocysteinemia Diseases 0.000 title claims abstract description 11
- 230000003225 hyperhomocysteinemia Effects 0.000 title claims abstract description 11
- 240000007594 Oryza sativa Species 0.000 claims abstract description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 6
- 235000009566 rice Nutrition 0.000 claims abstract description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 5
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 5
- 240000008042 Zea mays Species 0.000 claims abstract description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 5
- 235000007215 black sesame Nutrition 0.000 claims abstract description 5
- 235000005822 corn Nutrition 0.000 claims abstract description 5
- 235000019713 millet Nutrition 0.000 claims abstract description 5
- 241001165494 Rhodiola Species 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 244000042430 Rhodiola rosea Species 0.000 abstract description 3
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 2
- 235000018417 cysteine Nutrition 0.000 abstract description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 2
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 2
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 2
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗高同型半胱氨酸血症的组合物，其特征在于：由10‑15重量份大米、50‑70重量份小米、10‑20重量份玉米、1‑5重量份黑芝麻、3‑3.5重量份红景天、0.9‑1.0重量份地龙组成，本发明的有益效果是：本发明用于治疗高同型半胱氨酸血症的组合物一方面可以保证患者的营养部分，另一方面可以有效使得患者体内的同型半氨酸随尿液排出，该配比科学配比营养组分，稳定性好，且对身体无毒性，长期食用可使病情得到稳定的控制。
Description
技术领域
本发明涉及生物医药领域，具体涉及一种用于治疗高同型半胱氨酸血症的组合物。
背景技术
时下，冠心病、脑梗死等心血管疾病的发病率日渐高升高，除了传统的高血脂、高血压、高血糖等“三高”因素作祟外，还有一大祸根，那就是高同型半胱氨酸血症(homocystinuria，HCU)，又称高半胱氨酸血症，是由甲硫氨酸代谢障碍导致，引起甲硫氨酸代谢障碍有遗传和环境营养两种因素，其中遗传因素为三种酶即甲烯四氢叶酸还原酶(MTHFR)、胱硫醚缩合酶(CBS)、甲硫氨酸合成酶(MS)缺乏或活性降低，临床表现为患者早年发生动脉粥样硬化，且波及全身大、中、小动脉，病变弥漫且严重，环境营养因素则是代谢辅助因子叶酸、维生素B6、维生素B12的缺乏，该病的治疗方法可针对发病原因，一方面补充叶酸及维生素，另一方面通过控制饮食来限制甲硫氨酸的摄入。
发明内容
本发明所要解决的技术问题在于针对上述现有技术的不足，
提供一种用于治疗高同型半胱氨酸血症的组合物。
为实现上述目的，本发明提供了如下技术方案：一种用于治疗高同型半胱氨酸血症的组合物，其特征在于：由10-15重量份大米、50-70重量份小米、10-20重量份玉米、1-5重量份黑芝麻、3-3.5重量份红景天、0.9-1.0重量份地龙组成。
采用上述技术方案，将10-15重量份大米、50-70重量份小米、10-20重量份玉米、1-5重量份黑芝麻、3-3.5重量份红景天、0.9-1.0重量份地龙放入电饭锅中煮熟代替主食食用，限制甲流氨酸的摄入，可有效控制患者病情，并使得患者体内的同型半氨酸随尿液排出。
本发明的有益效果是：本发明用于治疗高同型半胱氨酸血症的组合物一方面可以保证患者的营养部分，另一方面可以有效使得患者体内的同型半氨酸随尿液排出，该配比科学配比营养组分，稳定性好，且对身体无毒性，长期食用可使病情得到稳定的控制。
具体实施方式
一种用于治疗高同型半胱氨酸血症的组合物，由10-15重量份大米、50-70重量份小米、10-20重量份玉米、1-5重量份黑芝麻、3重量份红景天、0.9-重量份地龙组成。
Claims (1)
1.一种用于治疗高同型半胱氨酸血症的组合物，其特征在于：由10-15重量份大米、50-70重量份小米、10-20重量份玉米、1-5重量份黑芝麻、3-3.5重量份红景天、0.9-1.0重量份地龙组成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110795802.6A CN113521208A (zh) | 2021-07-14 | 2021-07-14 | 一种用于治疗高同型半胱氨酸血症的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110795802.6A CN113521208A (zh) | 2021-07-14 | 2021-07-14 | 一种用于治疗高同型半胱氨酸血症的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521208A true CN113521208A (zh) | 2021-10-22 |
Family
ID=78127925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110795802.6A Pending CN113521208A (zh) | 2021-07-14 | 2021-07-14 | 一种用于治疗高同型半胱氨酸血症的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521208A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711890A (zh) * | 2004-06-22 | 2005-12-28 | 余世明 | 杂粮饭 |
| JP2009155278A (ja) * | 2007-12-27 | 2009-07-16 | Suntory Holdings Ltd | 高ホモシステイン血症改善剤 |
-
2021
- 2021-07-14 CN CN202110795802.6A patent/CN113521208A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711890A (zh) * | 2004-06-22 | 2005-12-28 | 余世明 | 杂粮饭 |
| JP2009155278A (ja) * | 2007-12-27 | 2009-07-16 | Suntory Holdings Ltd | 高ホモシステイン血症改善剤 |
Non-Patent Citations (2)
| Title |
|---|
| 杨士杰: "补阳还五汤加减联合叶酸治疗脑梗死恢复期伴高同型半胱氨酸血症的疗效分析", 《中国民间疗法》 * |
| 黄伟明: "中医浅析高同型半胱氨酸血症", 《中医临床研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koklesova et al. | Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person | |
| Loscalzo | Homocysteine trials—clear outcomes for complex reasons | |
| Jen et al. | Syndromes associated with nutritional deficiency and excess | |
| RU2352147C2 (ru) | Биологически активная добавка (варианты) | |
| US20160346266A1 (en) | Reduction or prevention of alcohol reaction with dietary supplements | |
| Bhargava et al. | Lowering homocysteine and modifying nutritional status with folic acid and vitamin B12 in Indian patients of vascular disease | |
| AU2010206796B2 (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
| US20100280123A1 (en) | Food supplement containing alpha-keto acids for supporting diabetes therapy | |
| US20050112210A1 (en) | Eye nutritional supplement | |
| WO2004016100A2 (en) | Nutritional supplement for adolescents | |
| US8728535B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| CN106072659A (zh) | 多元机体抗氧化营养素组合物及其应用 | |
| US7901710B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| WO2014022886A1 (en) | A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient | |
| US8263667B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| AU2010206791B2 (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
| Almeida et al. | Recommendations for folate intake in women: implications for public health strategies | |
| CN113521208A (zh) | 一种用于治疗高同型半胱氨酸血症的组合物 | |
| US20080226746A1 (en) | Nutritional supplement for women | |
| AU2015101086B4 (en) | A dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment | |
| Rivlin | Vitamin Defi ciencies | |
| WO2014143192A1 (en) | Reduction or prevention of alcohol reaction with dietary supplements | |
| Arise et al. | Chemical composition, sensory attributes and in vivo anti-diabetic effects of wheat-walnut composite flour-based croissants on streptozotocin-induced diabetic Wistar rats | |
| CN105394707A (zh) | 一种富硒酱油 | |
| Lundy | CWID 11447757 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |
|
| RJ01 | Rejection of invention patent application after publication |